



# Pediatric Medical Liver Disease

**Paul S. Dickman, M.D.**

Department of Pathology and Laboratory Medicine

Phoenix Children's Hospital

Departments of Child Health, Pathology & Pediatrics

University of Arizona

[pdickman@phoenixchildrens.com](mailto:pdickman@phoenixchildrens.com)



## PRESENTATION OUTLINE:

### I. Cholestatic Liver Disease

- A. Neonatal hepatitis
- B. Progressive familial intrahepatic cholestasis
- C. Paucity of intrahepatic ducts/Alagille syndrome
- D. Extrahepatic biliary atresia
- E.  $\alpha$ -1 Anti-trypsin deficiency
- F. Ductal plate malformations/ARPKD
- G. Wilson's disease



what is it, gall bladder?  
can't you see I have a  
lot to do?

I made  
these



you made STONES?



YOU'RE JUST SUPPOSED  
TO HOLD WHAT I GIVE YOU!

GET OUT! GO ON!



I made  
these



# I. Examples of cholestatic diseases:

| Mechanical obstruction   |  | Non-obstructive intrahepatic cholestasis   |   | Systemic illness  |
|--|--|--|---|---|
| Extrahepatic   | Intrahepatic   | Small bile duct/ranalicular  | Hepatocellular  |   |
| <b>Malignant</b> <ul style="list-style-type: none"> <li>Cholangiocarcinoma</li> <li>Pancreatic carcinoma</li> <li>Ampullary carcinoma</li> <li>Gall bladder carcinoma</li> <li>Metastases to lymph nodes in porta hepatis</li> </ul> <b>Benign</b> <ul style="list-style-type: none"> <li>Choledocholithiasis</li> <li>Primary sclerosing cholangitis</li> <li>Chronic pancreatitis</li> <li>AIDS cholangiopathy</li> <li>Congenital               <ul style="list-style-type: none"> <li>Choledochocoele</li> </ul> </li> </ul> | <b>Malignant</b> <ul style="list-style-type: none"> <li>Metastatic malignancy</li> </ul> <b>Benign</b> <ul style="list-style-type: none"> <li>Abscess</li> <li>Primary sclerosing cholangitis</li> <li>Suppurative cholangitis</li> <li>★ Congenital fibrosis</li> </ul> | <ul style="list-style-type: none"> <li>Primary biliary cirrhosis</li> <li>Primary sclerosing cholangitis</li> <li>Vanishing bile duct syndrome               <ul style="list-style-type: none"> <li>Chronic rejection in liver transplants</li> <li>Sarcoidosis</li> <li>Drugs</li> </ul> </li> <li>Inherited               <ul style="list-style-type: none"> <li>Benign recurrent cholestasis</li> <li>★ Progressive familial intrahepatic cholestasis</li> <li>Gilbert's syndrome</li> <li>Crigler-Najjar syndrome</li> <li>Dubin-Johnson syndrome</li> <li>Rotor syndrome</li> </ul> </li> <li>Cholestasis of pregnancy</li> </ul> | <ul style="list-style-type: none"> <li>Viral</li> <li>Alcoholic hepatitis</li> <li>Drug induced</li> <li>Autoimmune</li> <li>Malignant infiltration</li> <li>Vascular occlusion               <ul style="list-style-type: none"> <li>Budd-Chiari syndrome</li> <li>Portal vein thrombosis</li> </ul> </li> <li>Metabolic/Hereditary               <ul style="list-style-type: none"> <li>NAFLD/NASH</li> <li>Iron overload</li> <li>★ Wilson's disease</li> <li>★ Alpha<sub>1</sub>-antitrypsin deficiency</li> <li>Galactosaemia</li> <li>Tyrosinaemia</li> <li>Cystic fibrosis</li> </ul> </li> </ul> | <ul style="list-style-type: none"> <li>Right heart failure</li> <li>Haemolysis</li> </ul> |

AIDS = acquired immunodeficiency syndrome; NAFLD = non-alcoholic fatty liver disease; NASH = non-alcoholic steatohepatitis.



## A. Neonatal Hepatitis

- Multifactorial disorder with myriad pathogenetic mechanisms
- Diagnosis of exclusion based on adjunct testing :
  - Laboratory investigation
  - Electron microscopy
  - Imaging studies
  - Infectious disease work-up
  - Clinical features
  - Etc.




TABLE 12.2. Conditions Associated with Neonatal Hepatitis.

→ Idiopathic neonatal hepatitis

Infections, including cytomegalovirus, herpes virus, enterovirus (coxsackie B- and echovirus), rubella, hepatitis B, varicella, reovirus, paramyxovirus, parvovirus B19, toxoplasmosis, syphilis, toxoplasmosis, and bacterial sepsis (*Escherichia coli* and *Listeria*)

Metabolic conditions (see Table 12.3)

Endocrine, hypopituitarism

→ Obstructive, including biliary atresia, choledochal cyst

Chromosomal, including trisomy 17-18 syndrome, 21, and Monosomy X

Immune and hemolytic disorders (ABO and Rh incompatibility, spherocytosis, neonatal lupus erythematosus)

Total parenteral nutrition




TABLE 12.3. Metabolic Causes of Hepatitis (Neonatal or Acute).

Alpha-1-antitrypsin deficiency

Tyrosinemia

Bile acid synthesis disorders (oxysterol 7 $\alpha$  hydroxylase deficiency, 3 $\beta$  hydroxy steroid dehydrogenase deficiency and oxosteroid 5 $\beta$  reductase deficiency)

Alagille syndrome

Cystic fibrosis

Peroxisomal disorders (Zellweger syndrome, Refsum disease, di- and trihydroxycholestanic acidemia)

Familial intrahepatic cholestatic syndromes (progressive familial intrahepatic cholestasis II, North American Indian childhood cirrhosis)

Fructosemia

Galactosemia

Mitochondrial mtDNA depletion

Neonatal hemochromatosis

Gaucher disease

Niemann-Pick disease type C

Wilson's disease<sup>1</sup>

Indian childhood cirrhosis<sup>1</sup>

Ornithine transcarbamylase deficiency<sup>1</sup>

<sup>1</sup>Acute hepatitis pattern.






# Common Histological Features of Idiopathic Neonatal Hepatitis (INH):

- Pronounced giant cell transformation
- Portal and lobular inflammatory infiltrates
- Apoptotic bodies
- Bile ductular reaction



PHOENIX  
CHILDREN'S  
Hospital  
Department of Pathology


INH: Giant cell transformation, portal/periportal infiltrate with lobular spill  
(H&E x4)





PHOENIX  
CHILDREN'S  
Hospital  
Department of Pathology

INH: Feathery degeneration of hepatocytes, canalicular cholestasis and inflammation (H&E x 10).






PHOENIX  
CHILDREN'S  
Hospital

Department of Pathology

INH: Mixed acute/chronic inflammation with eosinophils.  
Note neutrophil in bile duct epithelium (arrow)


(H&E x 40).





PHOENIX  
CHILDREN'S  
Hospital  
Department of Pathology



INH: Canalicular and cytoplasmic cholestasis (arrows), extramedullary hematopoiesis (star), and giant cell transformation (H&E x 20)





PHOENIX  
CHILDREN'S  
Hospital  
Department of Pathology


INH: Moderate ductular proliferation (CK7 x 2) but no fibrosis  
(Masson trichrome x 2)





PHOENIX  
CHILDREN'S  
Hospital  
Department of Pathology

## INH: Microvesicular steatosis (H&E x 10).






PHOENIX  
CHILDREN'S  
Hospital

Department of Pathology


INH: Canalicular and cytoplasmic cholestasis, apoptotic body,  
and feathery degeneration with focal giant cell transformation  
(H&E x 20).







## Stage 2 fibrosis (Masson trichrome x 4).





INH: As possible causes are numerous, diagnosis often descriptive with suggestions for additional testing to determine etiology.

Helpful ancillary tests:

--Special stains:

iron, copper;

infections (CMV/HSV/Adenovirus) immunostains as  
CK7/CKAE1/AE3)

--Electron microscopy

--Quantification studies (iron/copper)

--Viral RT-PCR

--Serology




## B. Progressive Familial Intrahepatic Cholestasis (PFIC):

- Originally described in 1965 in Byler kindred of Pennsylvania Amish
- Different subtypes classified on molecular profile
  - All 3 types are caused by recessive mutations in different genes
- Benign recurrent intrahepatic cholestasis also described in 1965, now recognized as milder form of PFIC



## Canalicular membrane surface proteins, their substrates, and known associations with pediatric disease.




David Brambough, and Cara Mack Pediatrics in Review  
2012;37:291-292

PediatricsinReview



PHOENIX  
CHILDREN'S  
Hospital  
Department of Pathology


## PFIC I: Portal inflammation and ductopenia (H&E x 10)







PHOENIX  
CHILDREN'S  
Hospital  
Department of Pathology

PFIC I: Pale canalicular bile (arrow) (H&E x 40).






PFIC I: Mild to moderate portal and lobular fibrosis  
(Masson trichrome x 4); CK7 highlights ductular proliferation and  
hepatocytes (x 10).








## Ultrastructural feature of normal bile






PHOENIX  
CHILDREN'S  
Hospital  
Department of Pathology


# Granular (Byler) bile in PFIC I liver found on electron microscopy.








PFIC III: Chronic active hepatitis with brisk inflammation and portal-portal bridging (H&E x 4).





PHOENIX  
CHILDREN'S  
Hospital  
Department of Pathology


## PFIC III: Ductular hyperplasia and interface hepatitis (H&E x 20).





PHOENIX  
CHILDREN'S  
Hospital  
Department of Pathology

PFIC III: Ductular proliferation highlighted by CK7 (x 10); bridging fibrosis on Masson trichrome (x 4).







## Applicable Antibodies:

BSEP

MDR<sub>3</sub>

GGT



## C. Paucity of Intrahepatic Bile Ducts

Two general groups:

1. Syndromic

--Alagille syndrome (arteriohepatic dysplasia)

2. Non-syndromic

--Diseases in which paucity is associated with another identifiable condition:

--Infection (CMV, HSV, rubella)

--Immune abnormality , e.g. GVHD

--Hepatotoxicity

--Metabolic diseases (Zellweger syndrome, bile acid metabolism)

--Chromosomal abnormalities ( 45XO; trisomy 17, 18, 21)

--Extrahepatic biliary atresia

--Sclerosing cholangitis

--Langerhans cell histiocytosis

--Primary biliary cirrhosis




## C. Paucity of Intrahepatic Bile Ducts: Alagille syndrome epidemiology:

|                            |   |
|----------------------------|---|
| <b>Etiology</b>            | <ul style="list-style-type: none"> <li>• Autosomal dominant genetic disease</li> <li>• Mutations in the JAG-1 gene on chromosome 20p12 are responsible for AGS in more than 90 percent of patients; others have mutations in NOTCH-2</li> </ul>   |
| <b>Incidence</b>           | <ul style="list-style-type: none"> <li>• Approximately 1/100,000 live births</li> </ul>   |
| <b>Gender Ratio</b>        | <ul style="list-style-type: none"> <li>• There is equal gender distribution</li> </ul>  |
| <b>Age Predilection</b>    | <ul style="list-style-type: none"> <li>• The majority of patients present before six months of age</li> </ul>   |
| <b>Risk Factors</b>        | <ul style="list-style-type: none"> <li>• Mutation in the <i>Jagged1 (JAG1)</i> or <i>NOTCH2</i> gene</li> </ul>   |
| <b>Treatment</b>           | <ul style="list-style-type: none"> <li>• Currently no curable treatment exists and medical management depends on diagnosing and treating disease in each affected organ system</li> </ul>   |
| <b>Prognosis</b>           | <ul style="list-style-type: none"> <li>• Predicting prognosis is difficult; however, it is dependent on the severity of liver damage and cardiac complications</li> </ul>   |
| <b>Findings on Imaging</b> | <ul style="list-style-type: none"> <li>• ERCP: Narrowing of the extrahepatic biliary ducts and uniform narrowing of the intrahepatic ducts with reduced arborization</li> <li>• Cholescintigraphy: Delayed visualization of gastrointestinal tract</li> <li>• MR: Peripheral pulmonary stenosis. Structural abnormalities of the liver, with a combination of tumor-like nodules centered on a hypertrophic portal vessel and areas of major atrophy</li> <li>• CT: Peripheral pulmonary stenosis; Butterfly vertebrae</li> </ul> |

Table 1: Summary table of syndromic Alagille syndrome


# Features of Alagille Syndrome:



A | Slit-lamp eye exam with posterior embryotoxon (arrow). B | Classical cardiac abnormalities with frequency. C | MRI of renal arcuatus. D | Cerebral angiogram with moyamoya disease. E | Trichrome stain on liver demonstrating paucity of bile ducts. F | Characteristic facies: broad forehead, pointed chin, deep-set eyes. G | Butterfly vertebral bodies (arrow).




## Alagille syndrome (AS): Cholestasis and giant cell transformation (H&E x10).







AS: Portal tract with no bile ducts (H&E x 20).





PHOENIX  
CHILDREN'S  
Hospital  
Department of Pathology


AS: Portal tracts with CK7 and H&E demonstrating proliferating ductules but no bile ducts (each x 10).





PHOENIX  
CHILDREN'S  
Hospital  
Department of Pathology


AS: No bile ducts in portal tracts (H&E x 20).





PHOENIX  
CHILDREN'S  
Hospital  
Department of Pathology


AS: CK7 in hepatocytes and one possible bile duct in portal tract (x 20).





PHOENIX  
CHILDREN'S  
Hospital  
Department of Pathology

## Non-syndromic paucity of bile ducts: intense periportal inflammation (H&E x4)








PHOENIX  
CHILDREN'S  
Hospital

Department of Pathology


## Non-syndromic paucity of bile ducts (H&E x 20).





PHOENIX  
CHILDREN'S  
Hospital  
Department of Pathology


Non-syndromic paucity of bile ducts: Cytoplasmic and canalicular cholestasis with plugging (H&E x 40).





PHOENIX  
CHILDREN'S  
Hospital  
Department of Pathology

Non-syndromic paucity of bile ducts: Ductular proliferation highlighted on CK7; portal fibrosis on Masson trichrome (each x 10).








## D. Extrahepatic Biliary Atresia:

| Gene                 | IHBD   | EHBD        | Gallbladder                                 |
|----------------------|--|-------------|---|
| Jagged/Notch pathway | Abnormal   | No findings | No findings                                 |
| Hes1                 | No findings  | Hypoplasia  | Agnesis                                     |
| HNF6                 | Ductal plate malformation<br>IH biliary cysts        | Abnormal    | Agnesis                                     |
| HNF1 $\beta$         | Rarefaction of small IHBD<br>Dysplasia of large IHBD | Undefined   | Abnormal epithelium<br>Dilated cystic duct  |
| Foxf1                | Normal   | Undefined   | Small or absent<br>Without epithelial cells |
| Foxm1b               | Agnesis  | Undefined   | Undefined                                   |



## Extrahepatic biliary atresia types




Zukotynski, K, Babyn, P, Coombs, B, et al. Biliary atresia imaging. Medscape. <http://emedicine.medscape.com/article/406335-overview#a4>

- Type I: Obliteration of common bile duct with patent proximal bile ducts.
- Type IIa: Atresia of hepatic duct with cystic bile ducts at porta hepatis.
- Type IIb: Atresia of cystic duct, common bile duct, and hepatic ducts.
- Type III: Atresia of extrahepatic biliary tree and intrahepatic ducts of porta hepatis.




Common bile duct biopsy in biliary atresia. Left: Markedly fibrotic stroma with small ductular structures displaying pinpoint lumens. Right: CK7 stain (each x 4).





PHOENIX  
CHILDREN'S  
Hospital  
Department of Pathology

Biliary atresia: Liver wedge biopsy with bridging fibrosis.  
Left, H&E x 2; Right, trichrome x 2.









PHOENIX  
CHILDREN'S  
Hospital  
Department of Pathology

Biliary atresia: Ductal bile plugging; ductular proliferation  
on CK7 (H&E x10, CK7 x4).





# Liver resection after failed Kasai procedure.





Probes demonstrate no luminal connection of intrahepatic biliary tree with small intestine anastomosis.






## Macronodular cirrhosis with diffuse cholestasis and fibrosis.






PHOENIX  
CHILDREN'S  
Hospital  
Department of Pathology

EHBA: Portal fibrosis and proliferating ductules with ductal plugging and mild interface inflammation; hepatocytes have cytoplasmic cholestasis (right side) (H&E x 10).






Biliary atresia: Portal fibrosis and proliferating ductules with ductal plugging and mild interface inflammation; hepatocytes display cytoplasmic cholestasis (H&E x 10).



## Treatment for Extrahepatic Biliary Atresia: --Kasai hepatportoenterostomy:





## Complications after Kasai procedure:

1. Ascending cholangitis (most common)
2. Portal hypertension
3. Intrahepatic biliary cavities
4. Poor growth and malnutrition

**\*\*Biliary atresia is most common reason for pediatric liver transplant in the US**





## E. $\alpha$ -1 Anti-trypsin Deficiency

--Common cause of neonatal cholestasis

--Autosomal recessive disease causing low serum levels of alpha-1-antitrypsin (AAT) and leading to emphysema (80%, usually 20-39 years) and liver disease


-- $\alpha$ 1AT: 394 amino acid plasma glycoprotein synthesized predominantly by hepatocytes and encoded by gene at 14q31.3

-- $\alpha$ 1AT: Protease inhibitor (Pi) that inhibits neutrophil elastase released at sites of inflammation; also inhibits trypsin






## Conditions Associated with Alpha-1 Antitrypsin Deficiency





PHOENIX  
CHILDREN'S  
Hospital  
Department of Pathology



$\alpha_1$ AT: Liver displays bright intracytoplasmic eosinophilic globules in hepatocytes (arrows) near the limiting plate (H&E x 20).






PHOENIX  
CHILDREN'S  
Hospital  
Department of Pathology

$\alpha_1$ AT: H&E (left) and PAS-Diastase (right) demonstrating accumulations of  $\alpha_1$ -antitrypsin material (each x 20).






$\alpha$ 1AT: Liver with  $\alpha$ -1 antitrypsin deficiency showing marked fibrosis on reticulin (left) and Masson trichrome (right) (each x 2).





$\alpha_1$ AT: Electron micrograph with accumulations of  $\alpha$ -1 antitrypsin (arrows).



# Diagnostic Tests for Alpha<sub>1</sub>-Antitrypsin (AAT) Deficiency and Associated Disease Risks.

**Table 1.** Diagnostic Tests for Alpha<sub>1</sub>-Antitrypsin (AAT) Deficiency and Associated Disease Risks.<sup>a</sup>

| Inherited Genetic Variants† | Protein Phenotype‡ | Serum Protein Level§ | Molecular Genotype¶       | Risk of COPD       | Risk of Liver Disease |
|-----------------------------|--------------------|----------------------|---------------------------|--------------------|-----------------------|
| ZZ                          | Z                  | Very low             | ZZ                        | Very high          | High                  |
| ZNull                       | Z                  | Very low             | Z/non-S, non-Z            | Very high          | Unknown               |
| MZ                          | MZ                 | Intermediate         | Z/non-S, non-Z            | Possibly increased | Possibly increased    |
| MNull                       | M                  | Intermediate         | Non-S, non-Z/non-S, non-Z | Unknown            | None                  |
| SZ                          | SZ                 | Low                  | SZ                        | Increased          | Possibly increased    |
| NullNull                    | None               | None                 | Non-S, non-Z/non-S, non-Z | Very high          | None                  |



## $\alpha_1$ AT treatment:

- Augmentation therapy or infusion of purified  $\alpha_1$  anti-trypsin from pooled human plasma
- Liver transplantation





## F. Ductal Plate Malformation & Polycystic Kidney Disease:

### A. Small interlobular ducts

- Congenital hepatic fibrosis, ARPKD
- Biliary hamartomas

### B. Medium interlobular ducts

- AD Polycystic Liver Disease
  - Isolated form caused by 2 genes:
    - SEC63* and *PRKCSH*
  - Associated with ADPKD caused by 2 genes:
    - PKD1* and *PKD2*

### C. Large-sized intrahepatic ducts


- Caroli's disease

### D. Large extrahepatic ducts

- Choledochal cysts



# Normal bile duct development



**References:** Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University Graduate School of Medicine - Kyoto/JP





Fig. 2: Types of ductal plate malformation depending on duct size affected. References: Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University Graduate School of Medicine - Kyoto/JP



# Liver ultrasound showing dilated intrahepatic ducts.

RE


2D

71%

C 50

F Low

Gain




10. 20



TRANS RT LIVER

11

17  
3-6




ARPKD/CHF: Cirrhosis with ductal plate malformation. Note macronodular architecture of parenchyma and grey bands of **fibrosis** (x 2).






ARPKD/CHF: Dense bands of fibrosis,  
inflammatory infiltrates, and marked ductular proliferation  
(H&E x 4).






ARPKD/CHF: Dilated enlarged ducts at edge of limiting plate (H&E x 20).





ARPKD/CHF: CK7 positive in florid proliferation of small, intermediate and large ducts (x 4).









## ARPKD features:


- Early mortality most common due to pulmonary complications: 30-50% perinatal mortality, 80-95% 5 year survival after the first month of life
- 1:20,000 births
- Usually no cysts other than kidney/liver, but liver is always affected with ductal plate malformation and congenital hepatic fibrosis
- Caused by mutations in PKHD1 gene at locus 6p12

ARPKD: External and cut surfaces of kidney. Note effacement of entire cut surface and perpendicular orientation of cysts to renal capsule.





ARPKD: Kidney histology with multiple cystic structures (H&E x 2).  
Note presence of few glomeruli (circled).






## G. Wilson Disease (Hepatolenticular degeneration)


- AR disorder, 1:30,000; causes toxic copper accumulation in liver, brain and eyes
- Genetic abnormality on 13q14 producing ATP7B, a transmembrane copper-transporting ATPase
- Diagnosis: serum ceruloplasmin  $<20$  mg/dL ( $<5$ ), increased copper on liver biopsy, urinary copper excretion  $>50\mu\text{g}/24$  hr, liver copper quantification  $>250\mu\text{g/g}$  dry weight

Wilson disease: Abnormal *ATP7B* functionality leads to failure of conversion of apoceruloplasmin to ceruloplasmin and failure of conjugated copper to be excreted in bile. Results in toxic accumulation of copper in hepatocytes.





## Wilson disease: Additional sites of abnormal copper accumulation:



Kayser-Fleischer rings in eyes result from copper accumulating in Descemet's membrane at corneoscleral junction (limbus).



The 'Giant panda face' is typical on MRI when copper accumulates in midbrain.




# Wilson disease: Liver explant from WD patient with fulminant hepatic failure.








Wilson disease: Macronodular cirrhosis with scattered necrosis (arrows).






## Wilson disease: Necrosis surrounded by hemorrhage (H&E x 2).





PHOENIX  
CHILDREN'S  
Hospital  
Department of Pathology


Wilson disease: Effacement of normal architecture with bands of fibrosis containing proliferating bile ductules (Right: H&E x 4; Right, CK7 x 4).







PHOENIX  
CHILDREN'S  
Hospital  
Department of Pathology

Wilson disease: Steatosis, proliferating bile ductules and hepatocytic cholestasis (H&E x 10).






Wilson disease: Reticulin (left) and Masson trichrome (right) demonstrate dense bands of fibrosis (each x 2).






PHOENIX  
CHILDREN'S  
Hospital  
Department of Pathology

Wilson disease: Red-brown accumulations of copper in hepatocytes and Kupffer cells. (arrows) (rhodanine x 20).






## Wilson disease: Electron-dense deposits (arrows) of copper.



## Treatment for Wilson's Disease:



Long-term copper chelation therapy and/or liver transplantation





## Acknowledgement:

Sincere thanks to Steve Taylor, MHS, PA<sup>CM</sup> (ASCP) for assistance in creating this lecture.

